Patents Issued in December 3, 2020
  • DIABETES TREATMENT REGIMENS USING ALPHA, ALPHA-SUBSTITUTED LONG-CHAIN AMPHIPATHIC CARBOXYLATES
    Publication number: 20200375933
    Abstract: Disclosed are methods of treating of type 2 diabetes mellitus and associated conditions in humans by administering an ?,?-substituted long-chain dicarboxylic acid. In some of the disclosed methods the ?,?-substituted long-chain dicarboxylic acid is administered as add-on therapy to anti-diabetic Standard-of-Care treatment.
    Type: Application
    Filed: May 29, 2017
    Publication date: December 3, 2020
    Inventor: Jacob BAR-TANA
  • MCT-BASED NUTRITION BLEND FOR PROVIDING HEALTH BENEFITS IN ANIMALS
    Publication number: 20200375934
    Abstract: A method for weight loss comprising orally administering a composition comprising a therapeutically effective amount of medium chain triglycerides to the animal, where the medium chain triglycerides include caprylic acid.
    Type: Application
    Filed: May 29, 2020
    Publication date: December 3, 2020
    Inventors: Yuanlong Pan, Oscar Izquierdo, George Arthur Bailey Wells
  • ENHANCED DELIVERY OF A HYDROPHOBIC AGENT IN THE ORAL CAVITY BY COUPLING TO A HYDROPHILIC AGENT WITH CELLULAR ACTIVITY
    Publication number: 20200375935
    Abstract: The compounds herein may be used to form an oral treatment composition. An oral treatment composition according to the present disclosure may comprise a mixture of different ingredients that when combined together result in an improved delivery mechanism to treat teeth and soft tissues of oral cavity. Generally the invention can be used to treat an oral disorder by delivering an oral treatment composition to a surface within the oral cavity, wherein the oral treatment composition comprises a hydrophobic active agent and a hydrophilic agent. The hydrophobic active agent may be a bacterial biofilm dispersion agent, a bacterial biofilm inhibitor, or a fatty acid signaling agent.
    Type: Application
    Filed: May 6, 2020
    Publication date: December 3, 2020
    Inventor: Gary R. Jernberg
  • NOVEL REVERSIBLE NITROXIDE DERIVATIVES OF NITROALKENES THAT MEDIATE NITROSATING AND ALKYLATING REACTIONS
    Publication number: 20200375936
    Abstract: Various embodiments of this invention are directed to pharmaceutical compositions and methods for treating disease. The compositions of such embodiments include reversible nitroxide derivatives of nitroalkenes. The methods of various embodiments include administering an effective amount of any of these pharmaceutical compositions to a patient in need of treatment.
    Type: Application
    Filed: August 17, 2020
    Publication date: December 3, 2020
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Marco Fazzari, Bruce A. Freeman, Francisco J. Schopfer
  • MCT-BASED NUTRITION BLEND FOR PROVIDING HEALTH BENEFITS IN ANIMALS
    Publication number: 20200375937
    Abstract: A method for treating sarcopenia or muscle atrophy in an animal and a method of increasing weight gain, increasing fat gain, or maintaining lean body mass in an animal in need thereof, is provided. The methods can comprise orally administering a composition comprising a therapeutically effective amount of medium chain triglycerides to the animal.
    Type: Application
    Filed: May 29, 2020
    Publication date: December 3, 2020
    Inventor: Yuanlong Pan
  • Water Soluble Formulation
    Publication number: 20200375938
    Abstract: A formulation for solubilizing a water insoluble pharmaceutical agent is provided. The formulation comprises: a water-insoluble pharmaceutical agent, a detergent, an enzyme that breaks down lipids, proteins, and/or starches, a plasticizing agent, an emulsifying agent and an aqueous solvent. A method of making the formulation is also provided.
    Type: Application
    Filed: May 30, 2019
    Publication date: December 3, 2020
    Inventor: Pankaj Modi
  • EPIGALLOCATHECHIN GALLATE SOLUTION
    Publication number: 20200375939
    Abstract: A stable pharmaceutical or dermo-cosmetic aqueous solution of epigallocatechin gallate is provided. The present solution has improved EGCG solubility, stability and bioavailability.
    Type: Application
    Filed: November 21, 2018
    Publication date: December 3, 2020
    Inventors: Bernard DO, Muriel PAUL, Alain ASTIER
  • USE OF CANNABINOIDS AND TERPENES FOR TREATMENT OF ORGANOPHOSPHATE AND CARBAMATE TOXICITY
    Publication number: 20200375940
    Abstract: Pharmaceutical compositions in which isolated cannabinoid receptor modulators are optionally combined with terpene blends in a pharmaceutically acceptable carrier. Methods for treating or preventing a disease disorder dysfunction or condition caused by exposure to an organophosphate or carbamate acetylcholinesterase inhibitor with the inventive compositions are also disclosed.
    Type: Application
    Filed: August 1, 2020
    Publication date: December 3, 2020
    Applicant: KOTZKER CONSULTING LLC
    Inventor: Joseph Morgan
  • COMBINATION OF UNSAPONIFIABLE LIPIDS COMBINED WITH POLYPHENOLS AND/OR CATECHINS FOR THE PROTECTION, TREATMENT AND REPAIR OF CARTILAGE IN JOINTS OF HUMANS AND ANIMALS
    Publication number: 20200375941
    Abstract: The present invention relates to a composition for the protection, treatment and repair of cartilage in humans and animal joints. The composition contains a combination of unsaponifiable lipids together with one or more of polyphenols and/or catechins. The composition or kit may contain avocado:soybean unsaponifiables (ASU) and green tea.
    Type: Application
    Filed: August 19, 2020
    Publication date: December 3, 2020
    Inventors: Todd R. Henderson, Louis Lippiello, Charles Filburn, David Griffin
  • METHOD OF TREATING STIMULANT USE DISORDER USING A COMBINATION OF TOPIRAMATE AND PHENTERMINE
    Publication number: 20200375942
    Abstract: Combinations and methods for treating a subject experiencing or at risk of experiencing an undesired consequence of stimulant use are provided. The combinations include topiramate and phentermine. The methods include administering an effective dose of a combination of topiramate and phentermine to a subject. In some embodiments, the methods include administering an effective dose of a combination of topiramate and phentermine to a subject with cocaine use disorder.
    Type: Application
    Filed: June 1, 2020
    Publication date: December 3, 2020
    Inventor: Craig R. Rush
  • CYTOCIDAL METHOD OF CANCER CELLS SELECTIVELY IN HUMAN PATIENTS CLINICALLY BY DEPLETION OF L-ASCORBIC ACID, PRIMARILY, WITH ITS SUPPLEMENTATION ALTERNATELY AUGMENTING ITS CYTOCIDAL EFFECT
    Publication number: 20200375943
    Abstract: A method is provided for treating a patient with a disease. The method includes administration of a repeated cycle of alternation of a rapid depletion of L-ascorbic acid (LAA) and supplementation of a high dose of LAA, wherein the rapid depletion of LAA is achieved by blocking of LAA signal transduction and/or by blocking of LAA transporter to control growth of malignant cells in a body of the patient. Further, a pharmaceutical composition designed to perform at least one of: a blocking of a LAA signal transduction and/or a blocking of a LAA transporter is provided. The pharmaceutical composition may be used as a depletion means of LAA in a cyclic administration of the depletion of LAA followed by the high dose supplementation of LAA over a period of time.
    Type: Application
    Filed: May 28, 2020
    Publication date: December 3, 2020
    Inventor: Chan Hyung PARK
  • LIPOIC ACID CHOLINE ESTER COMPOSITIONS AND METHODS TO GENERATE BIOCOMPATIBLE OPHTHALMIC FORMULATIONS
    Publication number: 20200375944
    Abstract: The present invention describes ophthalmic lipoic acid choline ester compositions and specific processes to produce biocompatible formulations of said compositions suitable for the eye.
    Type: Application
    Filed: March 9, 2020
    Publication date: December 3, 2020
    Inventors: Shikha P. BARMAN, William R. BURNS, Kathryn S. CRAWFORD, Kevin L. WARD
  • INHALABLE FORMULATION OF A SOLUTION CONTAINING INDACATEROL MALEATE AND GLYCOPYRRONIUM BROMIDE
    Publication number: 20200375945
    Abstract: The present invention discloses a liquid, propellant-free pharmaceutical preparation and a method for administering a pharmaceutical preparation by nebulizing the pharmaceutical preparation in an inhaler. The propellant-free pharmaceutical preparation comprising: (a) active substances selected from glycopyrronium bromide and indacaterol maleate; (b) a solvent; and (c) a pharmacologically acceptable preservative, optionally including a pharmacologically acceptable stabilizer, a pharmacologically acceptable solubilizing agent, a pharmacologically acceptable co-solvent, or other pharmacologically acceptable additives.
    Type: Application
    Filed: June 2, 2020
    Publication date: December 3, 2020
    Inventors: Cai Gu Huang, Ying Ai Xu, Yue Zhao, Lu Lu Zhang
  • INHIBITORS OF METALLO-BETA-LACTAMASES
    Publication number: 20200375946
    Abstract: The present invention relates to certain compounds, in particular, indole derivatives that function as inhibitors of bacterial metallo-beta-lactamases. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of a bacterial infection.
    Type: Application
    Filed: November 30, 2016
    Publication date: December 3, 2020
    Inventors: Jürgen Brem, Anna M. Rydzik, Michael A. McDonough, Christopher J. Schofield, Angus Morrison, Joanne Hewitt, Andrew Pannifer, Philip Jones
  • (3AR)-1,3A,8-TRIMETHYL-1 ,2,3,3A,8,8A-HEXAHYDROPYRROLO[2,3-B]INDOL-5-YL PHENYLCARBAMATE AND METHODS OF TREATING OR PREVENTING NEURODEGENERATION
    Publication number: 20200375947
    Abstract: The invention includes an amount of (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate for administering to a subject and also a method of preventing or treating neurotoxicity or neurodegenerative processes in a subject in need thereof using the amount thereof.
    Type: Application
    Filed: August 17, 2020
    Publication date: December 3, 2020
    Applicant: ANNOVIS BIO, INC.
    Inventor: Maria Maccecchini
  • (3AR)-1,3A,8-TRIMETHYL-1 ,2,3,3A,8,8A-HEXAHYDROPYRROLO[2,3-B]INDOL-5-YL PHENYLCARBAMATE AND METHODS OF TREATING OR PREVENTING NEURODEGENERATION
    Publication number: 20200375948
    Abstract: The invention includes an amount of (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate for administering to a subject and also a method of preventing or treating neurotoxicity or neurodegenerative processes in a subject in need thereof using the amount thereof.
    Type: Application
    Filed: August 17, 2020
    Publication date: December 3, 2020
    Applicant: ANNOVIS BIO, INC.
    Inventor: Maria Maccecchini
  • BISPHENOL COMPOUNDS
    Publication number: 20200375949
    Abstract: The present disclosure provides compounds of formula (I) or salts thereof, wherein R1-R10 and x are defined herein; compositions containing these compounds; methods of inhibiting, reducing, or ameliorating bacterial growth on a substrate using these compound; and products such as dental care products, soaps, antibacterial products, and plastics comprise one or more compounds described herein.
    Type: Application
    Filed: November 21, 2018
    Publication date: December 3, 2020
    Inventors: Marisa C. KOZLOWSKI, Young Eun LEE, Thomas PANIAK, Cristian OCHOA, William M. WUEST, Amy E. SOLINSKI
  • 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS
    Publication number: 20200375950
    Abstract: The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders,
    Type: Application
    Filed: August 21, 2020
    Publication date: December 3, 2020
    Applicant: H. Lundbeck A/S
    Inventors: Jan Kehler, Karsten Juhl, Mauro Marigo, Paulo Jorge Vieira Vital, Mikkel Jessing, Morten Langgård, Lars Kyhn Rasmussen, Carl Martin Sebastian Clementson
  • DANTROLENE AND ANALOGS THEREOF FOR THE CHRONIC TREATMENT AND PREVENTION OF DYSSYNCHRONOUS CARDIAC DYSFUNCTION
    Publication number: 20200375951
    Abstract: The present disclosure relates to methods for the chronic treatment of dyssynchronous cardiac dysfunction (including non-arrhythmia cardiac dysfunction such as heart failure, cardiomyopathy, viral myocarditis, ischemia induced cardiomyopathy, ischemia, chemotheraphy, pacing induced cardiomyopathy or ion channel mutation related dysfunction) and for the prevention or treatment of diseases or conditions associated with dyssynchronous cardiac dysfunction. The method comprises chronically administering to a patient an effective amount of dantrolene, or derivative or analogs thereof (such as azumolene).
    Type: Application
    Filed: November 14, 2018
    Publication date: December 3, 2020
    Inventor: Kumaraswamy Nanthakumar
  • ANTI-CANCER AZOLE COMPOUNDS
    Publication number: 20200375952
    Abstract: Compounds comprising azole moieties are disclosed. The disclosed compounds are shown to have anticancer activity. Also disclosed are pharmaceutical composition of the compounds and method of their use in the treatment of cancer.
    Type: Application
    Filed: June 3, 2019
    Publication date: December 3, 2020
    Applicant: Imam Abdulrahman Bin Faisal University
    Inventors: Ayhan Bozkurt, Firdos Alam Khan, Seyda Tugba Gunday Anil
  • Methods of Treating Hepatorenal Syndrome and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists
    Publication number: 20200375953
    Abstract: The present invention is directed to methods of treating hepatorenal syndrome by administration of a therapeutically effective amount of a thromboxane A2 receptor antagonist to a patient in need thereof. The present invention is also directed to methods of treating hepatic encephalopathy and cerebral edema by administration of a therapeutically effective amount of a thromboxane A2 receptor antagonist to a patient in need thereof.
    Type: Application
    Filed: June 16, 2020
    Publication date: December 3, 2020
    Applicant: Cumberland Pharmaceuticals Inc.
    Inventors: Leo PAVLIV, Martin OGLETREE
  • THERAPEUTIC AGENT FOR FOOD COMPETENCE DISORDER IN STOMACH
    Publication number: 20200375954
    Abstract: A therapeutic agent for impaired gastric accommodation which contains as an active ingredient a compound represented by the general formula (1): (wherein R1 represents a hydrogen atom, a hydroxyl group or a halogen atom; A represents a furyl group, a thienyl group, a thiazolyl group or an oxazolyl group; R2 and R3 each represents an alkyl group with 1 to 5 carbon atoms; and n represents an integer of 2 to 4), or an acid addition salt thereof. Use of a therapeutic agent of the present invention greatly alleviates symptoms caused by said disorders, such as early satiety and bloating, because it improves relaxation of gastric fundus and impaired gastric accommodation.
    Type: Application
    Filed: August 20, 2020
    Publication date: December 3, 2020
    Applicant: ZERIA PHARMACEUTICAL CO., LTD.
    Inventors: Yugo MATSUNAGA, Shigeru UEKI, Hiroki KATO, Shiro KOBAYASHI
  • TREATMENT OF HEPATITIS DELTA VIRUS INFECTION
    Publication number: 20200375955
    Abstract: Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.
    Type: Application
    Filed: August 18, 2020
    Publication date: December 3, 2020
    Inventors: David A. Cory, Ingrid Choong, Jeffrey S. Glenn
  • PHARMACEUTICAL COMBINATION AND ITS USE FOR TREATING SYNUCLEINOPATHIES
    Publication number: 20200375956
    Abstract: The present invention describes the combination of a 6-propylamino-4,5,6,7-tetrahydro-1,3- benzothiazole-2-amine or of a pharmaceutically acceptable salt or solvate thereof with fluoxetine or a pharmaceutically acceptable salt or solvate thereof, for use for treating a synucleinopathy such as Parkinson's disease, Lewy body disease, mutations in the glucocerebrosidase gene, or multiple system atrophy.
    Type: Application
    Filed: April 11, 2018
    Publication date: December 3, 2020
    Applicant: CHASE THERAPEUTICS CORPORATION
    Inventors: Thomas N. CHASE, Kathleen E. CLARENCE-SMITH
  • COMPOSITIONS AND METHOD FOR TREATING DEPRESSION
    Publication number: 20200375957
    Abstract: The present invention describes the combination of a 5HT3-antagonist with pramipexole to reduce or eliminate the adverse effects associated with the use of pramipexole and to enable the use of high doses of pramipexole, useful for treating depressive disorders such as major depressive disorder.
    Type: Application
    Filed: April 23, 2018
    Publication date: December 3, 2020
    Applicant: CHASE THERAPEUTICS CORPORATION
    Inventors: Thomas N. CHASE, Kathleen E. CLARENCE-SMITH
  • MEMBRANE ACTIVE MOLECULES
    Publication number: 20200375958
    Abstract: A method of inducing anesthesia, sedation, and a method for treating disorders including central nervous system disorder, peripheral nervous system disorder, depression ischemia, and treatment with an anticonvulsant by administering an effective amount of a compound to a subject in need thereof.
    Type: Application
    Filed: April 23, 2018
    Publication date: December 3, 2020
    Inventors: James M. Sonner, John L. KRSTENANSKY
  • SOLID DISPERSION OF RIFAXIMIN
    Publication number: 20200375959
    Abstract: A solid dispersion of rifaximin comprising rifaximin and pharmaceutically acceptable carrier. A pharmaceutical composition comprising the solid dispersion of rifaximin.
    Type: Application
    Filed: May 6, 2020
    Publication date: December 3, 2020
    Applicant: Lupin Limited
    Inventors: Shirishkumar KULKARNI, Satish Kumar DALAL, Harshal Anil JAHAGIRDAR
  • USE OF GABOXADOL FOR THE TREATMENT OF TOURETTE SYNDROME, TICS AND STUTTERING
    Publication number: 20200375960
    Abstract: Treatment of Tourette syndrome using gaboxadol or a pharmaceutically acceptable salt thereof is provided. Treatment of tics using gaboxadol or a pharmaceutically acceptable salt thereof is provided. Treatment of stuttering using gaboxadol or a pharmaceutically acceptable salt thereof is provided. Therapeutic compositions that may be used to improve one or more symptoms of Tourette syndrome are provided. Therapeutic compositions that may be used to improve one or more symptoms of tics are provided. Also provided are therapeutic compositions that may be used to improve one or more symptoms of stuttering.
    Type: Application
    Filed: August 20, 2020
    Publication date: December 3, 2020
    Inventor: Matthew DURING
  • COMBINATION OF AN ANTIMUSCARINIC OR AN ANTICHOLINERGIC AGENT AND LIPOIC ACID AND USES THEREOF
    Publication number: 20200375961
    Abstract: The present disclosure relates to pharmaceutical compositions comprising a therapeutically effective amount of an antimuscarinic or an anticholinergic agent or a pharmaceutically acceptable salt or a stereoisomer thereof in combination with a therapeutically effective amount of lipoic acid or a pharmaceutically acceptable salt or a stereoisomer thereof. The antimuscarinic or anticholinergic agent is a compound of Formula I, Formula II, or Formula III and lipoic acid is a compound of Formula IV or Formula V. The Pharmaceutical composition is a physical mixture of an antimuscarinic or an anticholinergic agent and lipoic acid.
    Type: Application
    Filed: August 4, 2020
    Publication date: December 3, 2020
    Inventor: Mahesh Kandula
  • INDANE-AMINES AS PD-L1 ANTAGONISTS
    Publication number: 20200375962
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: January 14, 2020
    Publication date: December 3, 2020
    Inventors: Christopher LANGE, Sreenivas PUNNA, Rajinder SINGH, Ju YANG, Penglie ZHANG
  • TARGETING MITOCHONDRIAL COMPLEX II TO REDUCE EFFECTS OF CHRONIC HYPOXIA
    Publication number: 20200375963
    Abstract: Provided are methods for treatment of chronic systemic hypoxia. The method comprises administration of an inhibitor of mitochondrial complex II (MTCII). An example of an MTCII inhibitor is Atpenin 5.
    Type: Application
    Filed: February 9, 2018
    Publication date: December 3, 2020
    Inventor: Bora E. BAYSAL
  • DEMETHYLPENCLOMEDINE ANALOGS AND THEIR USE AS ANTI-CANCER AGENTS
    Publication number: 20200375964
    Abstract: This disclosure concerns novel demethylpenclomedine analogs. Also disclosed are pharmaceutical compositions and methods for using such compositions to treat hyperproliferative disorders.
    Type: Application
    Filed: August 17, 2020
    Publication date: December 3, 2020
    Applicant: Dekk-Tec, Inc.
    Inventor: Lee Roy Morgan
  • Targeting Lipid Metabolism and Free Fatty Acid (FFA) Oxidation to Treat Diseases Mediated by Resident Memory T Cells (TRM)
    Publication number: 20200375965
    Abstract: Methods for treating, or reducing risk of development or progression of, a tissue-resident memory T cells (TRM)-mediated disease, comprising administering a therapeutically effective amount of one or more inhibitors of exogenous lipid and free fatty acid uptake or of mitochondrial beta oxidation of internalized exogenous FFA (e.g., inhibitors of CD36 and/or FABP antagonists, e.g., inhibitors of FABP4 and/or FABP5, and/or CPT1) to a subject in need thereof.
    Type: Application
    Filed: February 15, 2019
    Publication date: December 3, 2020
    Inventors: Thomas S. Kupper, Rachael Clark, Youdong Pan
  • USE OF PRIDOPIDINE FOR THE TREATMENT OF ANXIETY AND DEPRESSION
    Publication number: 20200375966
    Abstract: The invention provides a method of reducing anxiety and/or depression in a subject comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to reduce anxiety and/or depression in a subject in the subject.
    Type: Application
    Filed: September 15, 2017
    Publication date: December 3, 2020
    Applicant: PRILENIA THERAPEUTICS DEVELOPMENT LTD
    Inventors: Michael HAYDEN, Mahmoud Abdulhossein POULADI
  • COMPOSITIONS OF PSILOCYBIN AND ANALOGS
    Publication number: 20200375967
    Abstract: Methods and compositions are disclosed for enhancing neurogenesis, resolving neuropathy and improving neurological health and functioning using fungal extracts and their active ingredients, including species of mushrooms and mycelia containing psilocybin and psilocin, combined with erinacines and hericenones or fungal extracts containing those active ingredients, with the addition of nicotinic acid. The compositions may optionally be combined with nervine plants.
    Type: Application
    Filed: August 13, 2020
    Publication date: December 3, 2020
    Inventor: Paul Edward STAMETS
  • APIXABAN FORMULATIONS
    Publication number: 20200375968
    Abstract: Compositions comprising crystalline apixaban particles having a D90 equal to or less than 89 ?m, and a pharmaceutically acceptable carrier, are substantially bioequivalent and can be used to for the treatment and/or prophylaxis of thromboembolic disorders.
    Type: Application
    Filed: May 14, 2020
    Publication date: December 3, 2020
    Inventors: Jatin Patel, Charles Frost, Jingpin Jia, Chandra Vemavarapu
  • PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6
    Publication number: 20200375969
    Abstract: Disclosed are compounds of Formula 1 and pharmaceutically acceptable salts thereof, wherein L, R4, R5, R8, R10, R11, X1, X2, X3, X9, X12, and Z are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with GPR6.
    Type: Application
    Filed: March 26, 2018
    Publication date: December 3, 2020
    Inventors: Jason Green, Maria Hopkins, Benjamin Jones, Andre A. Kiryanov, Jon Kuehler, Holger Monenschein, Sean Murphy, Thomas Nixey, Huikai Sun
  • THERAPEUTIC AGENT FOR HEPATOCELLULAR CARCINOMA
    Publication number: 20200375970
    Abstract: Disclosed is a therapeutic agent for hepatocellular carcinoma, comprising 5-((2-(4-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof.
    Type: Application
    Filed: March 26, 2019
    Publication date: December 3, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Atsumi Yamaguchi, Hajime Shimizu, Satoshi Goda, Saori Miyano
  • Use of CCR3-Inhibitors
    Publication number: 20200375971
    Abstract: The present invention relates to CCR3 inhibitors of formula 1, wherein R1 is H, C1-6-alkyl, C0-4-alkyl-C3-6-cycloalkyl, C1-6-haloalkyl; R2 is H, C1-6-alkyl; X is an anion selected from the group consisting of chloride or ½ dibenzoyltartrate j is 1 or 2. for use as a medicament for the treatment of diseases selected from dry age-related macular degeneration (dAMD), wet age-related macular degeneration (wAMD), retinopathy of prematurity (ROP), central retinal vein occlusion (CRVO), nasal polyposis, eosinophilic esophagitis, eosinophillic gastroenteritis (e.g. eosinophilic gastritis and eosinophilic ententeritis), hypereosinophilic syndrome and Churg Strauss syndrome.
    Type: Application
    Filed: August 19, 2020
    Publication date: December 3, 2020
    Inventors: Michael Chadham Nivens, Thierry Bouyssou, Peter Seither, Rolf Goeggel
  • FLAVORED NICOTINE POWDER
    Publication number: 20200375972
    Abstract: A nicotine powder inhaler (10) comprises a body extending between a mouthpiece portion (12) and a distal end portion (14), an airflow channel (15) extending between the mouthpiece portion and the distal end portion and a nicotine powder receptacle (20) disposed along the airflow channel, and a powder system disposed within the nicotine powder receptacle. The powder system includes a first plurality of particles having a particle size of about (10) micrometres or less and including nicotine and a second plurality of particles having a particle size of about 20 micrometres of greater and including flavour. The first plurality of particles comprise an amino acid or nicotine selected from the group consisting of nicotine pyruvate, nicotine mono-pyruvate, nicotine aspartate and nicotine lactate.
    Type: Application
    Filed: August 17, 2020
    Publication date: December 3, 2020
    Inventor: Gerard ZUBER
  • ADMINISTRATION OF DEUTERATED CFTR POTENTIATORS
    Publication number: 20200375973
    Abstract: Disclosed is a method of treating in a subject of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator The method comprises administering to the subject an amount in the range of about 50 mg to about 200 mg once a day of Compound (I) or (II): or pharmaceutically acceptable salts thereof. This invention also provides compositions comprising Compound (I) or (II) and the use of such compositions in methods.
    Type: Application
    Filed: May 14, 2020
    Publication date: December 3, 2020
    Inventor: Virginia Braman
  • PHOSPHODIESTERASE INHIBITOR TREATMENT
    Publication number: 20200375974
    Abstract: Methods and compositions are disclosed for the treatment of diseases or conditions produced by or associated with low cyclic nucleotide levels. The compositions comprise phosphodiesterase inhibitors and are formulated for intranasal and pulmonary administration.
    Type: Application
    Filed: December 23, 2019
    Publication date: December 3, 2020
    Inventor: Robert I. Henkin
  • Treatment of Renal Cell Carcinoma with Lenvatinib and Everolimus
    Publication number: 20200375975
    Abstract: Methods for treating a renal cell carcinoma with an improved combination of lenvatinib or a pharmaceutically acceptable salt thereof and everolimus are provided. These methods further comprises adjusting the dosages of lenvatinib during the onset of adverse effects to lead to improved treatment methods for human subjects with renal cell carcinoma. Particularly useful dosages and dose modifications upon the occurrence of adverse events are also provided.
    Type: Application
    Filed: August 19, 2020
    Publication date: December 3, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Alton KREMER, Corina DUTCUS
  • Method of Inhibiting Constitutively Active Phosphorylated FLT3 Kinase
    Publication number: 20200375976
    Abstract: The present invention includes a method of inhibiting or reducing deregulated FLT3 tyrosine kinase activity or FLT3 tyrosine kinase expression in a subject with a proliferative disease by administering to the subject having or suspected to have the proliferative disease, a therapeutically or prophylactically effective amount of the compound of Formula I: or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 19, 2020
    Publication date: December 3, 2020
    Inventor: Vinay K. Jain
  • NOVEL N-HYDROXYETHYL DIDEHYDROAZAPODOPHYLLOTOXINS AS GBP1 INHIBITORS AND METHODS OF OVERCOMING TREATMENT RESISTANCE IN CANCER
    Publication number: 20200375977
    Abstract: Compounds, compositions and methods are provided for the inhibition of GBP1. The subject inhibitor compounds can act by inhibiting GBP1 alone and/or GBP1: pro-survival kinase (e.g. serine/threonine-protein kinase pim-1 (PIM1)) interactions. Aspects of the subject methods include contacting a cellular sample with a GBP 1 inhibitor to inhibit the GBP 1 alone and/or GBP 1: PIM 1 interactions. Also provided are compositions and methods for treating cancer. In certain cases the cancer is resistant towards chemotherapy and radiation therapy.
    Type: Application
    Filed: March 12, 2019
    Publication date: December 3, 2020
    Inventors: Sanjay Malhotra, Vineet Kumar, Dhanir Tailor
  • TREATMENT OF CANCER
    Publication number: 20200375978
    Abstract: Provided are methods relating to compositions that include a CDP-topoisomerase inhibitor, e.g., a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101.
    Type: Application
    Filed: June 10, 2020
    Publication date: December 3, 2020
    Inventor: John Ryan
  • OPIOID FORMULATIONS
    Publication number: 20200375979
    Abstract: A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.
    Type: Application
    Filed: May 22, 2020
    Publication date: December 3, 2020
    Inventors: Fredrik Tiberg, Ian Harwigsson, Markus Johnsson
  • VETERINARY ANTIPROLACTINIC COMPOSITION
    Publication number: 20200375980
    Abstract: The present invention relates to a pharmaceutical or veterinary composition comprising an agonist of dopamine receptors, or a derivative thereof, for use in the prevention or decrease of delayed oestrus in sows, contributing thus to the synchronization of oestrus in sows in batch conductance management.
    Type: Application
    Filed: January 30, 2019
    Publication date: December 3, 2020
    Inventors: Thierry BERTAIM, Camille MANSANET, Naomie ISAKA
  • ENHANCEMENT OF IMPAIRED MOTOR AND MENTAL FUNCTIONS, USING DEXTROMETHORPHAN AND OXIDASE ENZYME INHIBITOR
    Publication number: 20200375981
    Abstract: During clinical trials on patients suffering from neurological disorders, it has been observed that some patients obtain dramatic improvements in motor control and/or higher mental functioning, when they receive a combination of dextromethorphan and quinidine, at suitable dosages. Improved motor control has been exemplified to date by improved ability to swallow and/or speak, among victims of stroke, head injury, or ALS. Improved higher mental functioning has been exemplified in better job performance, increased ability to analyze and solve problems, and increased ability to have successful and satisfying interactions with other people. These types of effects can be seen in a relatively brief time period, such as within several days to a week.
    Type: Application
    Filed: January 2, 2020
    Publication date: December 3, 2020
    Inventor: Richard A. SMITH
  • TREATMENT OF GLIOMAS USING ORGANONITRO COMPOUND COMBINATION THERAPY
    Publication number: 20200375982
    Abstract: The invention provides therapeutic methods and kits for treating a glioma using a particular dosing regimen of the organonitro compound ABDNAZ, radiation therapy, and one of temozolomide, irinotecan, or bevacizumab.
    Type: Application
    Filed: December 12, 2019
    Publication date: December 3, 2020
    Inventors: Bryan T. Oronsky, Jan Scicinski